Need Assistance?
  • US & Canada:
    +
  • UK: +

Ruminococcin-A

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Ruminococcin-A is an antibacterial peptide isolated from Ruminococcus gnavus. It has activity against gram-positive bacteria.

Category
Functional Peptides
Catalog number
BAT-011099
Molecular Formula
C119H180N32O35S4
Molecular Weight
2747.17
Synonyms
RumA; Gly-Asn-Gly-Val-Leu-Lys-Thr-Ile-Ser-His-Glu-Cys-Asn-Met-Asn-Thr-Trp-Gln-Phe-Leu-Phe
Purity
>96%
Sequence
GNGVLKTISHECNMNTWQFLF
1. Ruminococcin A, a new lantibiotic produced by a Ruminococcus gnavus strain isolated from human feces
J Dabard, C Bridonneau, C Phillipe, P Anglade, D Molle, M Nardi, M Ladiré, H Girardin, F Marcille, A Gomez, M Fons Appl Environ Microbiol. 2001 Sep;67(9):4111-8. doi: 10.1128/AEM.67.9.4111-4118.2001.
When cultivated in the presence of trypsin, the Ruminococcus gnavus E1 strain, isolated from a human fecal sample, was able to produce an antibacterial substance that accumulated in the supernatant. This substance, called ruminococcin A, was purified to homogeneity by reverse-phase chromatography. It was shown to be a 2,675-Da bacteriocin harboring a lanthionine structure. The utilization of Edman degradation and tandem mass spectrometry techniques, followed by DNA sequencing of part of the structural gene, allowed the identification of 21 amino acid residues. Similarity to other bacteriocins present in sequence libraries strongly suggested that ruminococcin A belonged to class IIA of the lantibiotics. The purified ruminococcin A was active against various pathogenic clostridia and bacteria phylogenetically related to R. gnavus. This is the first report on the characterization of a bacteriocin produced by a strictly anaerobic bacterium from human fecal microbiota.
2. Bioprocess Development for Lantibiotic Ruminococcin-A Production in Escherichia coli and Kinetic Insights Into LanM Enzymes Catalysis
Elvis L Ongey, Lara Santolin, Saskia Waldburger, Lorenz Adrian, Sebastian L Riedel, Peter Neubauer Front Microbiol. 2019 Sep 13;10:2133. doi: 10.3389/fmicb.2019.02133. eCollection 2019.
Ruminococcin-A (RumA) is a peptide antibiotic with post-translational modifications including thioether cross-links formed from non-canonical amino acids, called lanthionines, synthesized by a dedicated lanthionine-generating enzyme RumM. RumA is naturally produced by Ruminococcus gnavus, which is part of the normal bacterial flora in the human gut. High activity of RumA against pathogenic Clostridia has been reported, thus allowing potential exploitation of RumA for clinical applications. However, purifying RumA from R. gnavus is challenging due to low production yields (120 mg L-1 for the chimeric construct and >150 mg L-1 for RumM. The correlation observed between microscale and lab-scale bioreactor cultivations suggests that the process is robust and realistically applicable to industrial-scale conditions.
3. Heterologous Biosynthesis, Modifications and Structural Characterization of Ruminococcin-A, a Lanthipeptide From the Gut Bacterium Ruminococcus gnavus E1, in Escherichia coli
Elvis L Ongey, Robert T Giessmann, Michel Fons, Juri Rappsilber, Lorenz Adrian, Peter Neubauer Front Microbiol. 2018 Jul 26;9:1688. doi: 10.3389/fmicb.2018.01688. eCollection 2018.
Ruminococcin A (RumA) is a lanthipeptide with high activity against pathogenic clostridia and is naturally produced by the strict anaerobic bacterium Ruminococcus gnavus E1, isolated from human intestine. Cultivating R. gnavus E1 is challenging, limiting high-quality production, further biotechnological development and therapeutic exploitation of RumA. To supply an alternative production system, the gene encoding RumA-modifying enzyme (RumM) and the gene encoding the unmodified precursor peptide (preRumA) were amplified from the chromosome of R. gnavus E1 and coexpressed in Escherichia coli. Our results show that the ruminococcin-A lanthionine synthetase RumM catalyzed dehydration of threonine and serine residues and subsequently installed thioether bridges into the core structure of a mutant version of preRumA (preRumA*). These modifications were achieved when the peptide was expressed as a fusion protein together with green fluorescence protein (GFP), demonstrating that a larger attachment to the N-terminus of the leader peptide does not obstruct in vivo processivity of RumM in modifying the core peptide. The leader peptide serves as a docking sequence which the modifying enzyme recognizes and interacts with, enabling its catalytic role. We further investigated RumM catalysis in conjunction with the formation of complexes observed between RumM and the chimeric GFP fusion protein. Results obtained suggested some insights into the catalytic mechanisms of class II lanthipeptide synthetases. Our data further indicated the presence of three thioether bridges, contradicting a previous report whose findings ruled out the possibility of forming a third ring in RumA. Modified preRumA* was activated in vitro by removing the leader peptide using trypsin and biological activity was achieved against Bacillus subtilis ATCC 6633. A production yield of 6 mg of pure modified preRumA* per liter of E. coli culture was attained and considering the size ratio of the leader-to-core segments of preRumA*, this amount would generate a final yield of approximately 1-2 mg of active RumA when the leader peptide is removed. The yield of our system exceeds that attainable in the natural producer by several 1000-fold. The system developed herein supplies useful tools for product optimization and for performing in vivo peptide engineering to generate new analogs with superior anti-infective properties.
Online Inquiry
Verification code
Inquiry Basket